Andrew G Bosanquet

Summary

Publications

  1. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
  2. ncbi Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    J Exp Ther Oncol 4:145-54. 2004
  3. ncbi Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    Br J Haematol 146:384-95. 2009
  4. ncbi Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, School of Postgraduate Medicine, University of Bath, Bath, UK
    J Exp Ther Oncol 2:53-63. 2002
  5. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
  6. ncbi Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation
    Isrid Sturm
    Department of Hematology and Oncology, Charite, Campus Virchow Medical Center, Humboldt University, Berlin, Germany
    Int J Cancer 118:2329-36. 2006

Collaborators

Detail Information

Publications6

  1. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
    ..Here, we address the functional relevance of the codon 72 single nucleotide (SNP) polymorphism for cell death sensitivity following exposure to clinically employed cytotoxic drugs and gamma-irradiation...
  2. ncbi Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    J Exp Ther Oncol 4:145-54. 2004
    ..We conclude that further laboratory and clinical evaluation is required but the derived ex vivo therapeutic index could enhance choice of chemotherapy by reducing toxicity and/or improving efficacy...
  3. ncbi Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    Br J Haematol 146:384-95. 2009
    ..ITRT results could assist both in determining the best treatment for individual patients and in the design and rationale of future clinical trials...
  4. ncbi Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, School of Postgraduate Medicine, University of Bath, Bath, UK
    J Exp Ther Oncol 2:53-63. 2002
    ..Drug therapeutic index results are a valuable tool in identifying novel cytotoxic agents and individually tailored chemotherapy regimens...
  5. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
    ..This study demonstrates that HDMP alone or in combination with other agents is a useful treatment strategy in refractory CLL including patients with p53 abnormalities...
  6. ncbi Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation
    Isrid Sturm
    Department of Hematology and Oncology, Charite, Campus Virchow Medical Center, Humboldt University, Berlin, Germany
    Int J Cancer 118:2329-36. 2006
    ..Nevertheless, a poor prognosis was observed in patients with loss of APAF-1 expression and additional p53 mutation. Thus, loss of APAF-1 may become relevant when additional core apoptosis signaling components are disrupted...